Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.
| Website | https://ottimopharma.com |
| Employees | 19 (10 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Oncology, Cancer Therapies, Solid Tumors, Cancer Research, Drug Development, Targeted Therapy, Innovative Therapies, Drug Discovery, Biotechnology, Immunotherapy, Precision Medicine, Pharmaceutical, Biopharma, Pharmaceutical Research, Clinical Trials, Small Molecule Drugs, New Drug Applications |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck AH, AbbVie, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Pfizer +51 more (view full list) |
Looking for a particular Ottimo Pharma employee's phone or email?
Ottimo Pharma Questions
Robert Tighe is the Senior Vice President of Preclinical and Translational Sciences of Ottimo Pharma.
10 people are employed at Ottimo Pharma.
Top Ottimo Pharma Employees
-
Rick Anderson
Senior Vice President Finance at Ottimo Pharma
Everett, WA, US55+ -
35+
-
45+
-
23
-
Dannielle Hall
Director Clinical Operations at Ottimo Pharma
Boston, MA, US11 -
25+
-
11
